Alteration in urease-producing bacteria in the gut microbiomes of patients with inflammatory bowel diseases.
Abstract
Bacterial urease is a major virulence factor of human pathogens, and murine models have shown that it can contribute to the pathogenesis of inflammatory bowel diseases [IBD]. The distribution of urease-producing bacteria in IBD was assessed using public fecal metagenomic data from various cohorts, including non-IBD controls (n = 55), patients with Crohn's disease (n = 291), ulcerative colitis (n = 214), and patients with a pouch (n = 53). The ureA gene, and the taxonomic markers gyrA, rpoB and recA were used to estimate the percentage of urease producers in each sample. Levels of urease producers in patients with IBD and non-IBD controls were comparable. In non-IBD controls and most IBD patients, urease-producers were primarily acetate producing genera such as Blautia and Ruminococcus. A shift in the type of the dominant urease producers towards Proteobacteria and Bacilli was observed in a subset of all IBD subtypes, which correlated with fecal calprotectin levels in one cohort. Some patients with IBD had no detectable urease producers.In patients with a pouch the probiotic-associated species Streptococcus thermophilus was more common as a main urease producer than in other IBD phenotypes, and it generally did not co-occur with...Continue Reading
References
Related Concepts
Related Feeds
Bacteriotherapy
Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.
Bacteriotherapy (ASM)
Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.